Payment overview · 2025
General Payments
$284.20
15 reported records · 9 companies
Healthcare provider profile · identity verified
Frank Torres, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HARLINGEN, TX · NPI 1972500551
Verified facts
What the public records show
CMS Open Payments records show Frank Torres, M.D. received $284.20 in general payments during 2025 across 15 reported records.
GlaxoSmithKline, LLC. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.20 | 19.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.67 | 18.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.67 | 12.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.92 | 12.3% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $31.50 | 11.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.97 | 8.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.28 | 6.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.72 | 6.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.27 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.20 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $55.20 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.20 | 3 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1038 | 318 |
| Lisinopril | Lisinopril | 772 | 227 |
| Amlodipine Besylate | Amlodipine Besylate | 658 | 183 |
| Metformin Hcl | Metformin Hcl | 527 | 149 |
| Losartan Potassium | Losartan Potassium | 411 | 122 |
| Alprazolam | Alprazolam | 410 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 94 |
| Furosemide | Furosemide | 322 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 313 | 88 |
| Tradjenta | Linagliptin | 292 | 56 |
| Gabapentin | Gabapentin | 268 | 68 |
| Omeprazole | Omeprazole | 267 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 262 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 256 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 253 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 250 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 68 |
| Famotidine | Famotidine | 232 | 72 |
| Prednisone | Prednisone | 205 | 135 |
| Pioglitazone Hcl | Pioglitazone Hcl | 202 | 60 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 198 | 79 |
| Alendronate Sodium | Alendronate Sodium | 198 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 60 |
| Mirtazapine | Mirtazapine | 179 | 53 |
| Glimepiride | Glimepiride | 171 | 52 |
| Ibuprofen | Ibuprofen | 171 | 39 |
| Sertraline Hcl | Sertraline Hcl | 159 | 44 |
| Trazodone Hcl | Trazodone Hcl | 152 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 43 |
| Simvastatin | Simvastatin | 146 | 41 |
| Memantine Hcl | Memantine Hcl | 143 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 54 |
| Azithromycin | Azithromycin | 128 | 101 |
| Linzess | Linaclotide | 126 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 38 |
| Donepezil Hcl | Donepezil Hcl | 117 | 30 |
| Lorazepam | Lorazepam | 117 | 24 |
| Buspirone Hcl | Buspirone Hcl | 114 | 22 |
| Ozempic | Semaglutide | 110 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 43 |
| Desloratadine | Desloratadine | 103 | 23 |
| Meloxicam | Meloxicam | 103 | 23 |
| Carvedilol | Carvedilol | 89 | 24 |
| Finasteride | Finasteride | 87 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | 20 |
| Etodolac | Etodolac | 84 | 30 |
| Baclofen | Baclofen | 82 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 27 |
| Sucralfate | Sucralfate | 80 | 19 |
| Cephalexin | Cephalexin | 78 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 26 |
| Ondansetron Odt | Ondansetron | 78 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 77 | 26 |
| Jardiance | Empagliflozin | 76 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 18 |
| Allopurinol | Allopurinol | 73 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 22 |
| Levofloxacin | Levofloxacin | 73 | 55 |
| Mupirocin | Mupirocin | 73 | 38 |
| Farxiga | Dapagliflozin Propanediol | 72 | 20 |
| Ofloxacin | Ofloxacin | 72 | 39 |
| Cefdinir | Cefdinir | 71 | 51 |
| Rybelsus | Semaglutide | 71 | 14 |
| Valsartan | Valsartan | 70 | 18 |
| Eliquis | Apixaban | 69 | 16 |
| Clonidine Hcl | Clonidine Hcl | 67 | 18 |
| Spironolactone | Spironolactone | 67 | 20 |
| Cilostazol | Cilostazol | 65 | 12 |
| Celecoxib | Celecoxib | 64 | 17 |
| Tramadol Hcl | Tramadol Hcl | 64 | 22 |
| Naproxen | Naproxen | 62 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 14 |
| Potassium Chloride | Potassium Chloride | 60 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 48 |
| Clonazepam | Clonazepam | 59 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 58 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 17 |
| Glipizide | Glipizide | 55 | 18 |
| Hydrocortisone | Hydrocortisone | 55 | 26 |
| Jentadueto | Linagliptin/Metformin Hcl | 55 | suppressed |
| Aripiprazole | Aripiprazole | 53 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 17 |
| Montelukast Sodium | Montelukast Sodium | 52 | suppressed |
| Lactulose | Lactulose | 51 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 49 | 37 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 14 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Levetiracetam | Levetiracetam | 46 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 37 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 45 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 18 |
| Nystatin | Nystatin | 41 | 19 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 41 | 18 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Fluconazole | Fluconazole | 39 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Clotrimazole | Clotrimazole | 35 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 19 |
| Minocycline Hcl | Minocycline Hcl | 34 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 11 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Constulose | Lactulose | 23 | 11 |
| Glycopyrrolate | Glycopyrrolate | 23 | 12 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 17 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Techlite Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.20 · 15 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FASENRA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, JARDIANCE, MOUNJARO, Omnipod, PREVNAR 20, REXULTI, SHINGRIX | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error